> Inova Regional Trauma Center says the controversy over Northfield Laboratory's blood substitute caused it to suspend a planned trial. Report
> Adams Respiratory Therapeutics is buying back a manufacturing facility from Cardinal Health for $28 million. Report
> The FDA has extended its review period of an appeal from Epix Pharmaceuticals for the injectable imaging agent Vasovist. Report
> Nostrum Pharmaceuticals has obtained a worldwide license from the Institute of Microbial Technology in India to carry out clinical development and commercialization of a novel clot busting therapeutic protein. Release
> Recordati SpA is buying Portugal's Jaba group for €45 million. Report
> Zeltia has filed for European approval of its cancer drug Yondelis, which had been rejected in 2003. Report
> DanioLabs has begun a Phase I, proof-of-concept trial for DL06001 and DL06002 for sialorrhoea (drooling) and hyperhidrosis (excessive sweating) in Parkinson's disease. Report
And Finally… Drug makers spend millions of dollars each year to provide free lunches for physicians, all part of a huge marketing effort that has drawn growing criticism. Article